Partner Content Partner Content Managing Multi-Arm Studies in an Evolving Immuno-Oncology La... Collaborate with CROs and sites to help minimize risks
Partner Content Partner Content Beyond Immunotherapies Latest innovations emerging from immunotherapy research
News Merck KGaA to develop immunotherapies with F-star German Merck has option to licence LAG3-PDL1 drug.
Views & Analysis The cancer challenge: the quest for a cure is only half the ... The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
News Takeda signs deal with UK biotech GammaDelta Therapeutics on... UK biotech pioneering new type of T cell immunotherapy
Views & Analysis Deep Dive: Oncology magazine launched today Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
